Detection of hemizygous deletions in genomic DNA from leukaemia specimens for the diagnosis of patients

Leukemia Research

Volumn 29, Issue 2, 2005, Pages 165-171

  Kees, Ursula R ^a   Terry, Philippa A ^a   Ford, Jette ^a   Everett, Janet ^b   Murch, Ashleigh ^b   Klerk, Nick De ^a   Baker, David L ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Pathology   (Australia)

^c PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

Detection of gene deletion; Hemizygous; Leukaemia specimens; Polymerase chain reaction; Tumour suppressor genes

Indexed keywords

GENOMIC DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CANCER CYTODIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA DETERMINATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENOME ANALYSIS; HEMIZYGOSITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

ALLELES; BONE MARROW; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; EXONS; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 10644261368     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.05.021     Document Type: Article

References (24)

1. A.G. Knudson Jr. Hereditary cancer, oncogenes, and antioncogenes Cancer Res. 45 1985 1437 1443
2. W.D. Cook, and B.J. McCaw Accommodating haploinsufficient tumor suppressor genes in Knudson's model Oncogene 19 2000 3434 3438
3. R. Fodde, and R. Smits A matter of dosage Science 298 2002 761 763
4. K.H. Goss, M.A. Risinger, J.J. Kordich, M.M. Sanz, J.E. Straughen, and L.E. Slovek Enhanced tumor formation in mice heterozygous for Blm mutation Science 297 2002 2051 2053
5. S.B. Gruber, N.A. Ellis, K.K. Scott, R. Almog, P. Kolachana, and J.D. Bonner BLM heterozygosity and the risk of colorectal cancer Science 297 2002 2013
6. T.L. Carter, P.M. Watt, R. Kumar, P.R. Burton, G.H. Reaman, and H.N. Sather Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse Blood 97 2001 572 574
7. U.R. Kees, J. Ford, P.J. Price, B.F. Meyer, and R.P. Herrmann PER-117: a new human ALL cell line with an immature thymic phenotype Leuk. Res. 11 1987 489 498
8. U.R. Kees, J. Ford, M. Watson, A. Murch, M. Ringner, and R.L. Walker Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease Mol. Cancer Ther. 2 2003 671 677
9. U.R. Kees, P.R. Burton, C. Lu, and D.L. Baker Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome Blood 89 1997 4161 4166
10. L.M. Webber, and O.M. Garson Fluorodeoxyuridine synchronization of bone marrow cultures Cancer Genet. Cytogenet. 8 1983 123 132
11. U.R. Kees, R. Lukeis, J. Ford, M.L. Willoughby, and O.M. Garson Establishment and characterization of a childhood pre-B acute lymphoblastic leukemia cell line, PER-278, with chromosome translocations t(1;19) and t(1;9) Cancer Genet. Cytogenet. 46 1990 201 208
12. T.R. Golub, D.K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, and J.P. Mesirov Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286 1999 531 537
13. A.A. Alizadeh, M.B. Eisen, R.E. Davis, C. Ma, I.S. Lossos, and A. Rosenwald Distinct types of diffiuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
14. M. Hall, and G. Peters Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer Cancer Res. 68 1996 67 108
15. H.G. Drexler Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells Leukemia 12 1998 845 859
16. INK4A contributes to the outcome of cancer therapy Cell 109 2002 335 346
17. R. Bertin, C. Acquaviva, D. Mirebeau, C. Guidal-Giroux, E. Vilmer, and H. Cave CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia Genes Chromosomes Cancer 37 2003 44 57
18. A.H. Lund, G. Turner, A. Trubetskoy, E. Verhoeven, E. Wientjens, and D. Hulsman Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice Nat. Genet. 32 2002 160 165
19. S. Zhai, A.M. Senderowicz, E.A. Sausville, and W.D. Figg Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development Ann. Pharmacother. 36 2002 905 911
20. K.C. Quon, and A. Berns Haplo-insufficiency? Let me count the ways Genes Dev. 15 2001 2917 2921
21. H. Sasaki, M.C. Zlatescu, R.A. Betensky, Y. Ino, J.G. Cairncross, and D.N. Louis PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis Am. J. Pathol. 159 2001 359 367
22. B. Kwabbi-Addo, D. Giri, K. Schmidt, K. Podsypaninia, R. Parsons, and N. Greenberg Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression Proc. Natl. Acad. Sci. U.S.A. 98 2001 11563 11568
23. INK4A tumor suppressor gene is implicated as a predisposing factor in pediatric leukemia Biochem. Biophys. Res. Commun. 318 2004 852 855
24. A. Rosenwald, G. Wright, A. Wiestner, W.C. Chan, J.M. Connors, and E. Campo The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma Cancer Cell. 3 2003 185 197